CDKN2A and neoplasm: In particular, the frequency of CDKN2A LOF increased with more advanced tumor stage in all three cohorts (CDKN2A LOF incidence in early stage vs. advanced stage cohort 1 [N = 1144]: 28% vs. 35% p = 0.016; cohort 2 [N = 586]: 16% vs. 25% p = 0.015; cohort 3 [N = 183]: 12% vs. 28% p = 0.11).